Central AsianResearch Index

THE ROLE OF PIVKAII ONCOMARKER IN HEPATOCELLULAR CARCINOMA: А LITERATURE REVIEW

Relevance: Hepatocellular carcinoma (HCC) ranks sixth among the most common malignant neoplasms in the world and accounts for about 5.6% of all human malignant neoplasms. Despite encouraging progress in the diagnosis and treatment of HCC, the prognosis remains unsatisfactory, i.e., with a 5-year overall survival rate below 10.3%. However, the survival rate can reach 50-74% if early detection and therapeutic intervention are carried out on time. However, unfortunately, about 50% of HCC cases are diagnosed at a late stage. The protein induced by the absence of vitamin K or antagonist-II (PIVKA-II), also known as Dez-γ-carboxyprothrombin (DCP), is another marker specific to HCC. In several studies, elevated PIVKA-II serum levels were associated with HCC. Many authors have proven the PIVKA-II applicability for HCC monitoring. This study aimed to compare the efficiency of alpha-fetoprotein and des-gamma-carboxyprothrombin serological markers in HCC. Methods: The study included reviewing published articles on the causes of HCC and analyzing literature to compare cancer markers’ efficacy, including PIVKA-II and alpha-fetoprotein (AFP), in detecting HCC. Results: The published results evidence an important role of PIVKA-II in HCC early detection since PIVKA-II elevation in risk-group patients predicts HCC development in two years. Higher PIVKA-II levels can indicate a bigger tumor or a higher clinical stage. Besides, HCC patients with metastasis to the lymph nodes and distant metastasis had much higher PIVKA-II levels than non-metastatic patients. So, high PIVKA-II levels can, to a certain extent, reflect poor prognosis in HCC patients. Conclusion: The reviewed publications report much higher PIVKA-II serum levels in patients with HCC than in patients with benign liver diseases or healthy people. Besides, PIVKA-II has a higher diagnostic capacity than AFP due to its higher levels, sensitivity, and specificity. Thus, we can expect high sensitivity and efficiency of the PIVKA-II tumor marker in early HCC diagnostics.

Сведения

Опубликовано
2022 · Т. 66, № 4, С. 59-63
Язык
Английский
ISSN
1684-937X · 2521-6414
Издатель
Kazakh Institute of Oncology and Radiology
Аффилиации
1. «National Scientific Center of Surgery named after A.N. Syzganov» JSC 2. «Kazakh Institute of Oncology and Radiology» JSC
«National Scientific Center of Surgery named after A.N. Syzganov» JSC